Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Acute Kidney Injury | 14 | 2020 | 5762 | 1.13 | Why? |
| Creatinine | 3 | 2020 | 1443 | 0.91 | Why? |
| Critical Illness | 25 | 2021 | 17281 | 0.80 | Why? |
| Critical Care | 17 | 2021 | 14081 | 0.76 | Why? |
| Renal Circulation | 1 | 2018 | 44 | 0.73 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2018 | 107 | 0.72 | Why? |
| Neutropenia | 2 | 2018 | 388 | 0.71 | Why? |
| Vascular Resistance | 1 | 2018 | 148 | 0.69 | Why? |
| Cardio-Renal Syndrome | 1 | 2018 | 68 | 0.65 | Why? |
| Conflict of Interest | 1 | 2018 | 175 | 0.61 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.56 | Why? |
| Tumor Lysis Syndrome | 1 | 2013 | 5 | 0.54 | Why? |
| Research Support as Topic | 1 | 2018 | 327 | 0.54 | Why? |
| Urate Oxidase | 1 | 2013 | 11 | 0.53 | Why? |
| Glomerular Filtration Rate | 2 | 2017 | 1262 | 0.53 | Why? |
| Hyperphosphatemia | 1 | 2013 | 20 | 0.53 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.52 | Why? |
| Hematologic Neoplasms | 6 | 2020 | 2105 | 0.49 | Why? |
| Intensive Care Units | 29 | 2021 | 29594 | 0.49 | Why? |
| Attitude to Death | 1 | 2016 | 307 | 0.48 | Why? |
| Immunocompromised Host | 5 | 2020 | 5150 | 0.44 | Why? |
| Meta-Analysis as Topic | 1 | 2018 | 1289 | 0.43 | Why? |
| Nephrology | 1 | 2017 | 546 | 0.43 | Why? |
| Pneumonia, Ventilator-Associated | 5 | 2018 | 861 | 0.43 | Why? |
| Renal Replacement Therapy | 5 | 2018 | 1530 | 0.42 | Why? |
| Sepsis | 5 | 2018 | 3517 | 0.37 | Why? |
| Fluid Therapy | 3 | 2018 | 628 | 0.34 | Why? |
| Granulocyte Colony-Stimulating Factor | 2 | 2018 | 264 | 0.33 | Why? |
| Medical Staff, Hospital | 2 | 2018 | 1258 | 0.33 | Why? |
| Shock | 3 | 2019 | 1868 | 0.31 | Why? |
| Terminal Care | 1 | 2016 | 928 | 0.31 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 2 | 2021 | 284 | 0.29 | Why? |
| Respiratory Insufficiency | 7 | 2021 | 7301 | 0.26 | Why? |
| Pseudomonas Infections | 2 | 2018 | 425 | 0.26 | Why? |
| Neoplasms | 6 | 2020 | 17251 | 0.25 | Why? |
| Airway Extubation | 2 | 2018 | 403 | 0.24 | Why? |
| Palliative Care | 2 | 2017 | 2665 | 0.23 | Why? |
| Diet, Protein-Restricted | 1 | 2021 | 80 | 0.21 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.21 | Why? |
| Oxygen Inhalation Therapy | 3 | 2018 | 3629 | 0.21 | Why? |
| Proteoglycans | 2 | 2018 | 130 | 0.20 | Why? |
| Stress Disorders, Traumatic | 1 | 2020 | 78 | 0.20 | Why? |
| Complement C5 | 1 | 2020 | 139 | 0.20 | Why? |
| Parenteral Nutrition | 2 | 2017 | 184 | 0.19 | Why? |
| Early Diagnosis | 2 | 2019 | 2443 | 0.19 | Why? |
| Proportional Hazards Models | 8 | 2020 | 6543 | 0.19 | Why? |
| High-Frequency Ventilation | 1 | 2018 | 57 | 0.18 | Why? |
| Blood Transfusion | 2 | 2018 | 1399 | 0.18 | Why? |
| Common Variable Immunodeficiency | 1 | 2020 | 195 | 0.18 | Why? |
| Sepsis-Associated Encephalopathy | 1 | 2017 | 10 | 0.18 | Why? |
| Colloids | 1 | 2017 | 49 | 0.18 | Why? |
| Complement Inactivating Agents | 1 | 2020 | 254 | 0.18 | Why? |
| Enteral Nutrition | 2 | 2017 | 320 | 0.17 | Why? |
| France | 9 | 2021 | 12074 | 0.17 | Why? |
| Hypovolemia | 1 | 2018 | 65 | 0.17 | Why? |
| Isotonic Solutions | 1 | 2017 | 69 | 0.17 | Why? |
| Diagnostic Equipment | 1 | 2017 | 41 | 0.17 | Why? |
| Self-Assessment | 1 | 2018 | 165 | 0.16 | Why? |
| Pneumocystis carinii | 1 | 2018 | 205 | 0.16 | Why? |
| Pneumonia, Bacterial | 2 | 2021 | 843 | 0.16 | Why? |
| Humans | 61 | 2021 | 930598 | 0.16 | Why? |
| Pseudomonas aeruginosa | 2 | 2018 | 652 | 0.16 | Why? |
| Ultrasonography, Doppler | 1 | 2019 | 406 | 0.15 | Why? |
| Body Weight | 2 | 2019 | 1074 | 0.15 | Why? |
| Industry | 1 | 2018 | 347 | 0.14 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.14 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.14 | Why? |
| Organizational Culture | 1 | 2018 | 395 | 0.14 | Why? |
| Body Fluids | 1 | 2018 | 451 | 0.14 | Why? |
| Respiratory Sounds | 1 | 2017 | 294 | 0.13 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.13 | Why? |
| Pneumonia, Pneumocystis | 1 | 2018 | 322 | 0.13 | Why? |
| beta-Glucans | 1 | 2016 | 176 | 0.13 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Prospective Studies | 12 | 2020 | 43301 | 0.13 | Why? |
| Bicarbonates | 1 | 2013 | 33 | 0.13 | Why? |
| Erythrocyte Transfusion | 1 | 2017 | 386 | 0.13 | Why? |
| Allopurinol | 1 | 2013 | 59 | 0.13 | Why? |
| Hemodynamics | 2 | 2021 | 1562 | 0.13 | Why? |
| Nutritional Support | 1 | 2017 | 447 | 0.12 | Why? |
| Respiration | 1 | 2018 | 729 | 0.12 | Why? |
| Standard of Care | 2 | 2017 | 1297 | 0.12 | Why? |
| Risk Factors | 11 | 2020 | 71621 | 0.12 | Why? |
| Phenotype | 2 | 2021 | 4037 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.12 | Why? |
| Respiration, Artificial | 6 | 2021 | 22116 | 0.12 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.12 | Why? |
| Invasive Fungal Infections | 1 | 2016 | 274 | 0.12 | Why? |
| Resuscitation | 1 | 2017 | 638 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.11 | Why? |
| Tumor Burden | 1 | 2013 | 369 | 0.11 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.11 | Why? |
| Male | 31 | 2021 | 367725 | 0.11 | Why? |
| Female | 31 | 2021 | 380317 | 0.11 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.11 | Why? |
| Hematology | 1 | 2017 | 649 | 0.10 | Why? |
| Patient Positioning | 1 | 2021 | 1505 | 0.10 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.10 | Why? |
| Remission Induction | 1 | 2013 | 950 | 0.10 | Why? |
| Hospital Mortality | 6 | 2020 | 22087 | 0.10 | Why? |
| Prone Position | 1 | 2021 | 1861 | 0.10 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.09 | Why? |
| Organ Dysfunction Scores | 3 | 2020 | 1475 | 0.09 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.09 | Why? |
| Anti-Bacterial Agents | 4 | 2018 | 10083 | 0.09 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.09 | Why? |
| Aged | 21 | 2021 | 215776 | 0.09 | Why? |
| Organ Transplantation | 2 | 2020 | 2616 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.09 | Why? |
| Disease-Free Survival | 1 | 2013 | 1654 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Noninvasive Ventilation | 2 | 2018 | 2329 | 0.09 | Why? |
| Adult | 18 | 2021 | 244371 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Teaching | 1 | 2016 | 1208 | 0.08 | Why? |
| Platelet Transfusion | 2 | 2018 | 209 | 0.08 | Why? |
| Depression | 2 | 2021 | 14116 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Survivors | 1 | 2018 | 2619 | 0.08 | Why? |
| Intubation, Intratracheal | 2 | 2020 | 3962 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Needs Assessment | 1 | 2016 | 2352 | 0.08 | Why? |
| Antihypertensive Agents | 1 | 2018 | 1962 | 0.07 | Why? |
| Time-to-Treatment | 2 | 2020 | 5883 | 0.07 | Why? |
| Anxiety | 2 | 2021 | 17311 | 0.07 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| Cannula | 2 | 2021 | 750 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.06 | Why? |
| Quality Improvement | 1 | 2016 | 2435 | 0.06 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.06 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.06 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Models, Statistical | 1 | 2019 | 5312 | 0.06 | Why? |
| Physicians | 1 | 2021 | 4214 | 0.06 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2018 | 3892 | 0.06 | Why? |
| Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.06 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.06 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.05 | Why? |
| Acute Disease | 3 | 2018 | 6029 | 0.05 | Why? |
| Propensity Score | 2 | 2021 | 2690 | 0.05 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.05 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.05 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Respiratory Function Tests | 2 | 2018 | 1755 | 0.05 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.05 | Why? |
| Biomedical Research | 2 | 2018 | 5270 | 0.05 | Why? |
| Time Factors | 6 | 2020 | 31397 | 0.05 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 5277 | 0.05 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.05 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.05 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.05 | Why? |
| Treatment Outcome | 6 | 2018 | 51732 | 0.05 | Why? |
| Drug Therapy, Combination | 1 | 2013 | 7268 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Urinalysis | 1 | 2020 | 218 | 0.05 | Why? |
| Preliminary Data | 1 | 2020 | 457 | 0.05 | Why? |
| Hematuria | 1 | 2020 | 284 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.04 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.04 | Why? |
| Artificial Organs | 1 | 2017 | 18 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2018 | 242 | 0.04 | Why? |
| Cell Transplantation | 1 | 2017 | 21 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Cloning, Organism | 1 | 2017 | 21 | 0.04 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Paris | 1 | 2021 | 1287 | 0.04 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Glasgow Coma Scale | 1 | 2017 | 249 | 0.04 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.04 | Why? |
| Africa, Northern | 1 | 2017 | 539 | 0.04 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.04 | Why? |
| Internship and Residency | 1 | 2016 | 4987 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Length of Stay | 3 | 2017 | 11042 | 0.03 | Why? |
| Allografts | 1 | 2018 | 761 | 0.03 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Kidney | 2 | 2020 | 3648 | 0.03 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.03 | Why? |
| Streptococcus pneumoniae | 1 | 2018 | 827 | 0.03 | Why? |
| Physical Examination | 1 | 2018 | 755 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2018 | 22971 | 0.03 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.03 | Why? |
| Metabolic Diseases | 1 | 2017 | 505 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Health Care Surveys | 1 | 2020 | 2942 | 0.03 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Delirium | 1 | 2017 | 1061 | 0.02 | Why? |
| Hospitalization | 1 | 2018 | 54280 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Burnout, Professional | 1 | 2021 | 2489 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.02 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.02 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.01 | Why? |
| Logistic Models | 1 | 2016 | 9089 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.01 | Why? |
| Models, Theoretical | 1 | 2018 | 6659 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Stress, Psychological | 1 | 2020 | 10231 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Lung | 1 | 2018 | 31049 | 0.01 | Why? |
Darmon's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(239)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(186)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_